Potential Ways to Address Shortage Situations of 99Mo/99mTc

99mTc, the most common radioisotope used in nuclear medicine, is produced in a nuclear reactor from the decay of 99Mo. There are only a few aging nuclear reactors around the world that produce 99Mo, and one of the major contributors, the National Research Universal (Canada), ceased production on October 31, 2016. The National Research Universal produced approximately 40% of the world’s 99Mo supply, so with its shut down, shortages of 99Mo/99mTc are expected.

The article conducts a study based on interviews and survey questionnaires. The responses identify 6 categories of strategies: changes in imaging schedules, reduction of ordered doses or elimination of backup doses, alternative imaging protocols, generator management, contractual agreements with commercial nuclear pharmacies, and software use.

The supply chain of 99Mo/99mTc is quite fragile; therefore, being aware of the most appropriate coping strategies is crucial. It is essential to build a strong collaboration between the nuclear pharmacy and nuclear medicine department during a shortage situation. With both nuclear medicine departments and nuclear pharmacies implementing viable strategies, such as the ones proposed, the amount of 99mTc available during a shortage situation can be maximized.

To read more please visit http://tech.snmjournals.org/content/45/1/1.full

Source: Journal of Nuclear Medicine Technology